Structured page family:Cost guide
Vosoritide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Vosoritide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Voxzogo pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Vosoritide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$30,000-$40,000/month
Average wholesale price
~$28,000-$38,000/month
Pharmacy acquisition estimate
~$26,000-$35,000/month
Typical negotiated rate
~$22,000-$30,000/month
Price per dose
~$1,000 per daily injection (weight-based)
Annual cost at list price
~$360,000-$480,000
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Specialty pharmacy | $30,000-$40,000/month | REMS-required |
Insurance Coverage Landscape
Commercial plans
~60-70% with genetic diagnosis
Medicare Part D
Rare; case-by-case
Medicaid
Some states cover with extensive documentation
VA coverage
Case-by-case
TRICARE
Case-by-case
Employer plan typical tier
Tier 5 specialty; max out-of-pocket
Prior Authorization Guide
Required Documentation
- •Genetic confirmation of achondroplasia
- •Open growth plates (bone age)
- •Age 5-14 years
- •Pediatric endocrinologist attestation
Common Denial Reasons
- •No genetic test
- •Closed growth plates
- •Outside approved age range
- •Not prescribed by pediatric endocrinologist
Appeal Template Points
- •FDA-approved for achondroplasia
- •Genetic test attached
- •Open growth plates confirmed
- •No alternative therapy
- •First-ever treatment for this condition
Expected timeline: 2-4 weeks
Savings Programs and Patient Assistance
BioMarin PAP
manufacturerEligibility: Uninsured/underinsured
Savings: May provide at reduced or no cost
Income limit: Case-by-case
Enrollment: complex
Extensive application
Copay assistance
copayEligibility: Commercially insured
Savings: May reduce to $0
Income limit: None
Enrollment: moderate
Annual cap
Generic and Biosimilar Status
No generic currently available
Expected: No generic expected
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 15 mcg/kg daily | $30,000-$40,000 | $360,000-$480,000 |
Annual Cost Projection
Year 1
$0-$480,000
Year 2
$0-$480,000
Year 3
$0-$480,000
Assumptions
- •Ultra-rare genetic disease
- •Insurance variable
Cost-Saving Strategies
- 1.Genetic testing and specialist documentation are essential
- 2.Apply for BioMarin PAP immediately if coverage gaps
- 3.Work with patient advocate for appeals
- 4.Explore state rare disease programs
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | NHS specialized commissioning | NICE evaluation |
Need help comparing vosoritide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a vosoritide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Vosoritide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Vosoritide Cost FAQ
Sources
- 1. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.N Engl J Med • 2019Claim type: clinicalView source →
- 2. FDA Information on VosoritideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.